OBJECTIVES: To study the impact of protease inhibitor monotherapy on the HIV-1 blood reservoir in 72 antiretroviral-naive patients. PATIENTS AND METHODS: This was evaluated for 72 antiretroviral-naive patients included in the on-treatment analysis of the MONARK trial; 46 patients receivinglopinavir/ritonavir monotherapyand 26 patients receiving a triple therapy. HIV-DNA was quantified in whole blood, using real-time PCR. RESULTS: The decrease in HIV-DNA after 48 weeks of lopinavir/ritonavir monotherapy was similar to the decrease observed with triple therapy including lopinavir/ritonavir (-0.77 versus -0.69 log copies/10(6) leucocytes, respectively; P = 0.91). The HIV-DNA decrease was also similar in patients with a virological response in both arms (-0.69 versus -0.69 log copies/10(6) leucocytes, respectively). Interestingly, non-responders had a significantly higher baseline HIV-DNA load than responders in the monotherapy arm; 3.16 versus 2.86 log copies/10(6) leucocytes, respectively (P = 0.05). CONCLUSIONS: The MONARK data indicate that a lopinavir/ritonavir monotherapy regimen is potent against HIV blood reservoirs in antiretroviral-naive patients after 1 year of treatment, in comparison with a standard-of-care highly active antiretroviral therapy. This impact should be evaluated with other boosted protease inhibitor monotherapies.
RCT Entities:
OBJECTIVES: To study the impact of protease inhibitor monotherapy on the HIV-1 blood reservoir in 72 antiretroviral-naive patients. PATIENTS AND METHODS: This was evaluated for 72 antiretroviral-naive patients included in the on-treatment analysis of the MONARK trial; 46 patients receiving lopinavir/ritonavir monotherapy and 26 patients receiving a triple therapy. HIV-DNA was quantified in whole blood, using real-time PCR. RESULTS: The decrease in HIV-DNA after 48 weeks of lopinavir/ritonavir monotherapy was similar to the decrease observed with triple therapy including lopinavir/ritonavir (-0.77 versus -0.69 log copies/10(6) leucocytes, respectively; P = 0.91). The HIV-DNA decrease was also similar in patients with a virological response in both arms (-0.69 versus -0.69 log copies/10(6) leucocytes, respectively). Interestingly, non-responders had a significantly higher baseline HIV-DNA load than responders in the monotherapy arm; 3.16 versus 2.86 log copies/10(6) leucocytes, respectively (P = 0.05). CONCLUSIONS: The MONARK data indicate that a lopinavir/ritonavir monotherapy regimen is potent against HIV blood reservoirs in antiretroviral-naive patients after 1 year of treatment, in comparison with a standard-of-care highly active antiretroviral therapy. This impact should be evaluated with other boosted protease inhibitor monotherapies.
Authors: Pierre Gantner; Firouze Bani-Sadr; Rodolphe Garraffo; Pierre-Marie Roger; Michèle Treger; Thomas Jovelin; Pascal Pugliese; David Rey Journal: PLoS One Date: 2016-10-31 Impact factor: 3.240
Authors: Sidonie Lambert-Niclot; Philippe Flandre; Marc-Antoine Valantin; Cathia Soulie; Slim Fourati; Marc Wirden; Sophie Sayon; Sophie Pakianather; Laurence Bocket; Bernard Masquelier; Georges Dos Santos; Christine Katlama; Vincent Calvez; Anne-Genevieve Marcelin Journal: PLoS One Date: 2012-07-25 Impact factor: 3.240
Authors: Juan Pasquau; Carmen Hidalgo-Tenorio; María Luisa Montes; Alberto Romero-Palacios; Jorge Vergas; Isabel Sanjoaquín; José Hernández-Quero; Koldo Aguirrebengoa; Francisco Orihuela; Arkaitz Imaz; María José Ríos-Villegas; Juan Flores; María Carmen Fariñas; Pilar Vázquez; María José Galindo; Isabel García-Mercé; Fernando Lozano; Ignacio de Los Santos; Samantha Elizabeth de Jesus; Coral García-Vallecillos Journal: PLoS One Date: 2018-04-12 Impact factor: 3.240